Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Single-Day Packs Among OTC Packaging Innovations Needed – Consultant

This article was originally published in The Tan Sheet

Executive Summary

Making OTC drugs available in blister packs containing a single day's supply could reinforce appropriate dosing, according to packaging consultant Ed Bauer

You may also be interested in...



Tailored Dosing Devices Could Improve Compliance, FDA's Levy Says

Tailored Dosing Devices Could Improve Compliance, FDA's Levy Says

Prilosec OTC Packaging Change Gives Consumers Easier Access

Packaging changes for Procter & Gamble's Prilosec OTC proton-pump inhibitor are intended to make it easier to remove the product, according to brand executive Matt Champion

FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down

FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel